SAN FRANCISCO--(BUSINESS WIRE)--Oct 21, 2026--
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men. It’s the largest expansion of the company’s men’s health program since first introducing the category last September, giving eligible men more options to treat low testosterone in partnership with licensed providers through Hims.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021048006/en/
An estimated 20 million men 1,2 in the U.S. are affected by low testosterone, which, when left untreated, can lead to feelings of lower energy, reduced muscle mass, lower sex drive, and erectile dysfunction. For years, stigma kept many men quiet about these symptoms, but new research suggests men are starting to open up. A new survey commissioned by Hims of 2,000 U.S. men ages 18 and older found that men are speaking more openly about testosterone, and the hormonal shifts that come with age. When asked about what they actually want, 79% of men surveyed say more energy is a higher priority than more muscle, 3 so they can show up more fully at work, in their hobbies and with the people who matter most. Despite this progress, awareness of treatment hasn’t caught up: the same study shows fewer than half of men surveyed (45%) say they're familiar with specific low T treatments. 4
Starting today, Hims is closing that gap, providing eligible customers access to three new treatment options, including:
“Good testosterone care starts with a strong relationship between a customer and their provider,” said Mike Chi, Chief Operating Officer at Hims & Hers. “Everything we’ve developed, from at-home testing and follow-up labs to ongoing provider support, is designed to make that relationship easier to start and sustain. With injectable and oral TRT, more men can start, and stay on track, with support at every step.”
These new options build on Hims’ existing Testosterone Rx+ treatment, which includes enclomiphene, an ingredient shown to double testosterone levels ^ by boosting the body’s natural hormone production. Since introducing its testosterone offering, Hims has focused on reaching the many men living with low T, building an experience around at-home blood collection and provider-guided treatment that adapts over time. That approach is resonating. As of the second quarter, testosterone was scaling faster than any specialty outside of weight loss, just three quarters after its launch. %
“Different men need different care approaches, from encouraging the body's own testosterone production to replacing testosterone directly," said Pete Stahl, MD, SVP of Men's Health. "Our full set of treatment options gives our partnered clinicians more ways to deliver personalized, proactive care for testosterone deficiency to our customers.”
Many men with low testosterone go undiagnosed, often because getting tested has traditionally meant booking an appointment, going to a lab, and raising a sensitive topic in person. Hims built its diagnostic experience to remove those barriers, with clinical rigor at every step. Every customer begins with a detailed medical intake that assesses symptoms and screens for risk factors. Customers then collect a blood sample at home with a simple-to-use Tasso® device, an FDA-cleared, push-button collector worn on the upper arm, with no lab visit or venous draw required. From that single, small sample, Hims’ lab x tests 22 biomarkers, including total and free testosterone, SHBG, an advanced lipid panel, and glycemic markers, giving providers a far fuller picture of a man’s health than a standalone testosterone test. A licensed provider reviews symptoms, health history, and lab results in a live visit, and treatment is only prescribed when it’s medically appropriate. For those who begin treatment, ongoing assessments, follow-up lab testing, and continued access to a support team helps providers track progress and adjust care over time.
For more information, visit https://www.hims.com/testosterone.
About Hims & Hers Health, Inc.
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “over time,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, the launch and availability of injectable and oral testosterone replacement therapy offerings on the Hims & Hers platform, including their expected clinical effects, and the potential effects of these offerings and our broader men’s health program on customer outcomes and our business. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the rollout of our testosterone treatment options, and the related customer adoption and response; the safety, efficacy, and clinical outcomes of testosterone therapies, including compounded and commercially available products; changes in the application, interpretation, and enforcement of healthcare, drug compounding, telehealth, controlled substance, and consumer protection laws or regulations applicable to our business; and our ability to maintain the supply, quality, and availability of the products and services underlying these offerings, and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of October 21, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Not available in all 50 states. Labs and prescription required. Testosterone by Hims is a holistic program that includes lab testing, ongoing clinical support, technological tools, and medication prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions. Kyzatrex® is a registered trademark of Marius Pharmaceuticals, Inc. Tasso®, Tasso+® and the Tasso® logo are trademarks of Tasso Inc. Hims, Inc. is not affiliated with or endorsed by Marius Pharmaceuticals, Inc. or Tasso Inc. © 2026 Hims & Hers Health, Inc.
ˣ Lab tests are ordered by a healthcare provider and processed in a CLIA-certified lab. They do not diagnose conditions. Review results with your provider. Not available in Hawaii. Eligibility and provider order required. Insights and action plans include recommendations that encourage you to take action that may help improve your health. Lab results alone are not intended to diagnose, treat, or cure any condition. A provider will reach out about critical results and plans include access to 24/7 provider messaging.
% As of Q2, 2026
Citations:
1 Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A., & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International journal of clinical practice, 60(7), 762–769. https://doi.org/10.1111/j.1742-1241.2006.00992.x
2 National Population by Characteristics: 2020-2022. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2022 (NC-EST2022-SYAEXN). U.S. Census Bureau. https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html. Accessed 8/11/23
3 Based on August 2026 external survey data of 2,000 U.S. men ages 18+. Respondents were asked which they prioritize more in their life: more energy or more muscle. The research was commissioned by Hims & Hers Health, Inc. and conducted by Culture Co-op.
4 Based on August 2026 external survey data of 2,000 U.S. men ages 18+. 45% selected at least one of seven listed low testosterone treatments they were familiar with. The research was commissioned by Hims & Hers Health, Inc. and conducted by Culture Co-op.
* National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 441404, Testosterone Cypionate. https://pubchem.ncbi.nlm.nih.gov/compound/Testosterone-Cypionate
** Schulte-Beerbühl, M., & Nieschlag, E. (1980). Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertility and sterility, 33(2), 201–203. https://www.sciencedirect.com/science/article/pii/S0015028216445437
*** Bernstein, J. S., & Dhingra, O. P. (2024). A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Therapeutic advances in urology, 16, 17562872241241864. https://doi.org/10.1177/17562872241241864
^ Thomas, J., Suarez Arbelaez, M. C., Narasimman, M., Weber, A. R., Blachman-Braun, R., White, J. T., Ledesma, B., Ghomeshi, A., Jara-Palacios, M. A., & Ramasamy, R. (2023). Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study. Cureus, 15(7), e41476. https://doi.org/10.7759/cureus.41476
Hims Expands Testosterone Care with Injectable and Oral TRT
President Donald Trump and Vice President JD Vance on Tuesday announced a $25 million program to encourage the public to blow the whistle on suspected fraud in the U.S. government as they ramp up efforts to end the abuse of federal programs and dollars.
Meanwhile, Republican Vivek Ramaswamy ’s team confirmed late Tuesday that it produced a controversial advertisement featuring the estranged mother of Amy Acton, and the campaign says it will spend $4 million to promote it despite facing bipartisan rebuke for dredging up the painful childhood of his Democratic opponent in Ohio’s governor’s race.
Here's the latest:
Rubio said Ukraine would no longer exist if it wasn’t for U.S. support.
Rubio’s comments to reporters in Mumbai, India, came as the administration has been taken to task for curtailing intelligence sharing and the supply of weaponry for Ukraine. He said the administration would no longer take such criticism without a response.
“We’re no longer going to be defensive about this topic. If it were not for the assistance of the United States, including under the Trump administration, there would be no Ukraine right now,” Rubio said. “Ukraine as a sovereign state would not exist.”
U.S. Secretary of State Marco Rubio is insisting that President Trump and the U.S. government more broadly had nothing to do with interruptions to Ukraine’s access to crucial satellite data that Ukrainian officials say have compromised their ability to counter Russian attacks.
Speaking to reporters in India on Wednesday, Rubio said for the third time in four days that any throttling of network access to Ukraine was not directed or ordered by Trump or anyone else in his administration. He suggested, though, that the owner of the system, Elon Musk, may have been involved.
“What I can tell you with certainty is the president of the United States nor anyone in our system ever requested that any changes to that system be made, and that’s what we said repeatedly,” Rubio said. “The president has nothing to do with the decisions that are made by Starlink and Starshield and by Mr. Musk. That’s a private company. The president doesn’t run that company and can’t direct that company to do anything.”
That’s Neil Bush, the brother of one Republican president and the son of another, who authored a long Facebook post Tuesday night saying he voted early, and for Talarico over Republican Senate candidate Ken Paxton.
Bush said his decision was two-pronged. Paxton’s past, particularly his spearheading of a failed lawsuit to challenge the 2020 election results, “was an affront to our democratic institutions,” Bush wrote. Those who have “enabled” Trump, he continued, “have done enormous damage to the Republican Party.”
Turning to Talarico, Bush noted that he’d never met the candidate, but that he’s been “enormously impressed” and has seen “integrity, civility, humility” and an openness to listen to those who disagree with him.
“I have been a Republican for most of my life, and I still believe deeply in many traditional Republican principles,” Bush wrote, “but character matters more than party affiliation.”
Some Republican lawmakers are reacting with dismay in response to Trump special envoy Steve Witkoff’s praise of Russian President Vladimir Putin as a “humanitarian.”
“No. Putin is stone cold killer,” said Republican Sen. John Cornyn in a social media post on X.
“Another embarrassment,” said Republican Rep. Don Bacon, including a clip of Witkoff’s remarks, in his post.
“What an embarrassing and outrageous thing to say,” said Republican Sen. Thom Tillis of North Carolina. “You should go back to Ukraine and ask the families of the children Putin has kidnapped and murdered whether they agree your friend Putin is a ‘humanitarian.’”
Witkoff’s description came as he thanked Putin for releasing an American who had been jailed for more than four years on charges of fighting as a mercenary in Ukraine.
Collins made the campaign stop at a hot dog restaurant in Maine on Wednesday morning with former Sen. Joe Manchin as she tries to win reelection to her seat.
Collins, a five-term Republican senator, is in a tough reelection fight with Democrat Troy Jackson. Manchin touted her as a longtime moderate voice during a brief appearance after the morning campaign event.
Manchin, a longtime Democrat who became an independent shortly before retiring from the Senate, called Collins “the soul of the Senate.”
The two are also scheduled to appear at a New Balance sneaker facility in Maine later Wednesday.
To voter Roy Lyons, Los Angeles has been losing luster for years. A homeless crisis endures despite billions of dollars of spending. City Hall’s budget keeps swelling — as do the taxes needed to support it.
As the retired insurance broker from the Sherman Oaks neighborhood ponders his pick in the upcoming mayoral election, he’s leaning toward the unpopular incumbent, Mayor Karen Bass, over her fellow progressive Democrat Nithya Raman, a little-known city council member who’s backed by the Democratic Socialists of America. She endorsed Bass before changing her mind and entering the race.
Neither choice gives him confidence about the future.
“Is this the best we can do?” asked Lyons, a Democrat, who attended a recent candidate forum. “I don’t think either one shines.”
If Bass wins the Nov. 3 election, it will be because she was able to persuade voters like Lyons to give her a second chance after a rough first term that included the deadly Palisades Fire, which ignited when she was out of the country and caught the fire department unprepared.
▶ Read more
Russian President Vladimir Putin’s foreign affairs adviser Yuri Ushakov told reporters after a meeting between Putin and U.S. President Donald Trump’s envoy Steve Witkoff that the Russian leader has agreed “in principle” to resume the trilateral talks after Nov. 10.
Witkoff held talks with Putin in St. Petersburg on Wednesday about Moscow’s full-scale invasion of Ukraine, as Trump pushes Kyiv to make a deal that stops the fighting.
▶ Read more
The Justice Department’s inspector general has declined to investigate the handling of the criminal case against a former Olympian cleared of accusations that he intentionally damaged the Lincoln Memorial Reflecting Pool, according to a letter Wednesday from the man’s lawyers.
The internal watchdog told David Hearn’s lawyers the allegations of professional misconduct they made fall outside its jurisdiction and are instead within the purview of the department’s Office of Professional Responsibility, according to the letter, which urges Inspector General Don R. Berthiaume to reconsider the decision.
“Given the substantial public attention devoted to this matter, and the significant questions raised concerning the conduct of federal officials, declining independent review would risk undermining public confidence in the Department’s ability to police its own conduct. Such a result would be inconsistent with the purposes for which Congress established the OIG and would be a betrayal of its mission,” the letter says.
▶ Read more
The White House says the administration is using every tool available to stop foreign-based organized criminal organizations that exploit Americans online.
According to data supplied by the White House, federal authorities have seized more than 500 fraudulent cryptocurrency investment websites.
They’ve also interrupted millions of social media, email and internet accounts used by foreign criminal organizations to hunt victims in America, and have identified and warned nearly 9,000 people while they were in the process of being victimized, preventing an estimated $562 million in losses.
President Trump will visit South Carolina on Wednesday to boost Sen. Darline Graham, whose stumbles in her first campaign since replacing her late brother have Democratic voters hopeful — but not necessarily optimistic — their candidate can break Republicans’ grip on the state.
Although South Carolina isn’t typically a midterm battleground, Trump has been deeply invested in Graham. He supported her appointment to replace Lindsey Graham after his death in July, and he backed her in a special primary when she faced several more experienced Republican opponents.
Now the party wants to make sure Annie Andrews, the Democratic nominee and a pediatrician, doesn’t pull off an upset victory. More than $34 million has flowed into the race, and Republicans have hammered Andrews as a “radical liberal” and accused her of supporting surgeries for transgender minors, which she denies.
▶ Read more
Russia on Wednesday freed an American who’d been jailed for more than four years on charges of fighting as a mercenary in Ukraine, in a deal completed during a visit by a top U.S. envoy and at a time when President Trump has taken a series of actions meant to benefit Moscow.
Trump said in a Truth Social post that he had asked Russian President Vladimir Putin during a phone call last week to free Stephen Hubbard, and that, unlike previous releases, his had not required the U.S. to give up anyone in return.
“Welcome home, Stephen, it’s great to have you back,” Trump said.
Hubbard, a 74-year-old former teacher from Michigan, was on his way home following a visit to St. Petersburg by U.S. envoy Steve Witkoff, who also held talks with Putin about Moscow’s full-scale invasion of Ukraine, as Trump pushes Kyiv to make a deal that stops the fighting.
▶ Read more
The Ukrainian president told Fox News on Wednesday that he would agree to a ceasefire with Russia, freezing control of land as it currently stands more than four years since Russia invaded Ukraine, provided the U.S. provides security guarantees as a permanent peace deal is negotiated.
“Freeze and talks and security guarantees,” Zelenskyy said.
Still, Zelenskyy said during the interview that Ukraine does not want to yield any land permanently.
“They are not winning on the battlefield,” he said of Putin’s forces. That’s why Putin is trying to “push us from our land” at the negotiating table, Zelenskyy said. “It’s not fair.”
Republican Vivek Ramaswamy ’s team confirmed late Tuesday that it produced a controversial advertisement featuring the estranged mother of Amy Acton, and the campaign said it will spend $4 million to promote it despite facing bipartisan rebuke for dredging up the painful childhood of his Democratic opponent in Ohio’s governor’s race.
The decision exacerbates a deeply personal element in one of the country’s most closely watched and expensive campaigns for state office. Questions about the video will likely shadow Ramaswamy, a biotech billionaire who previously ran for president but has never before held public office, in the final two weeks of the contest. Democrats said he was growing desperate at a moment when more than 676,000 people have already cast ballots in Ohio.
The advertisement features Acton’s birth mother, Donna Arthur, calling her “a liar” and insinuating she has mental health issues. Acton, Ohio’s former public health director, has made no secret of facing homelessness and abuse as a child. Arthur lost custody of her children after their stepfather was indicted for raping Acton.
Acton spent Tuesday condemning Ramaswamy for the ad even before his campaign confirmed its provenance.
▶ Read more
President Donald Trump and Vice President JD Vance on Tuesday announced a $25 million program to encourage the public to blow the whistle on suspected fraud in the U.S. government as they ramp up efforts to end the abuse of federal programs and dollars.
The White House said that under the Fraud Whistleblower Incentive Program, anyone who submits a tip that leads to a fraud conviction or a significant federal enforcement action is eligible to receive up to $30,000, and that the Justice Department will administer the program.
During the announcement, Trump said payments will amount to a 1% commission on the amount of fraud the tip helps uncover. Trump also said he will decide who gets reward money in cases where more than one person claims to have provided the tip.
“I will be the arbitrator of all of these decisions,” Trump said in the Oval Office with Vance and other administration officials standing behind him. “It’ll be a binding arbitration.”
▶ Read more
President Donald Trump arrives on Air Force One, Tuesday, Oct. 20, 2026, at Joint Base Andrews, Md. (AP Photo/Alex Brandon)
President Donald Trump speaks in the Oval Office of the White House, Tuesday, Oct. 20, 2026, in Washington, as Vice President JD Vance listens. (AP Photo/Jacquelyn Martin)
